Safety and Efficacy of Maximally Tolerated RAS Therapy Alone or in Combination With Spironolactone in Diabetic Kidney Disease: Effect on Proteinuria and eGFR in the MRA-ACE Trial
Publication/Presentation Date
11-2022
Volume
33
Issue
11
First Page
677
Last Page
677
Published In/Presented At
Tumlin, James A.1,2; Kopyt, Nelson P.1; Wilson, Daniel J.1; NephroNet Clinical Trials Consortium. Safety and Efficacy of Maximally Tolerated RAS Therapy Alone or in Combination With Spironolactone in Diabetic Kidney Disease: Effect on Proteinuria and eGFR in the MRA-ACE Trial: SA-PO271. Journal of the American Society of Nephrology 33(11S):p 677, November 2022. | DOI: 10.1681/ASN.20223311S1677c
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS